Mizuho raised the firm’s price target on Edwards Lifesciences (EW) to $95 from $87 and keeps an Outperform rating on the shares post the Q2 report. The company posted a strong performances across its portfolio, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Early notable gainers among liquid option names on July 25th
- Edwards Lifesciences price target raised to $95 from $90 at Stifel
- Edwards Lifesciences price target raised to $80 from $77 at Evercore ISI
- Edwards Lifesciences price target raised to $79 from $78 at Baird
- Edwards Lifesciences price target raised to $89 from $85 at RBC Capital